Nicola Tyson

513 total citations
6 papers, 376 citations indexed

About

Nicola Tyson is a scholar working on Genetics, Pathology and Forensic Medicine and Rheumatology. According to data from OpenAlex, Nicola Tyson has authored 6 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Pathology and Forensic Medicine and 2 papers in Rheumatology. Recurrent topics in Nicola Tyson's work include Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Rheumatoid Arthritis Research and Therapies (2 papers). Nicola Tyson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Rheumatoid Arthritis Research and Therapies (2 papers). Nicola Tyson collaborates with scholars based in United Kingdom, United States and Sweden. Nicola Tyson's co-authors include Clifton O. Bingham, Ronald van Vollenhoven, Edward Keystone, Paul Emery, Roy Fleischmann, Patricia B. Lehane, Daniel E. Fürst, Neil Collinson, Jeff P. Sharman and John C. Byrd and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Nicola Tyson

6 papers receiving 369 citations

Peers

Nicola Tyson

PFM

GENET

IMMUN

RHEUM

HEMAT

Noriyuki Chiba Japan

Ravi Rao United Kingdom

Shuntaro Saito Japan

I.M. Markusse Netherlands

Sheila Kelly United States

Beata Stella‐Hołowiecka Poland

T. Tison Italy

Peter Meeus Belgium

Fedra Irazoque-Palazuelos Mexico

Takahiko Kurasawa Japan

Noriyuki Chiba Japan

Nicola Tyson

99 ×0.5

PFM

88 ×0.6

GENET

53 ×0.4

IMMUN

227 ×1.7

RHEUM

67 ×1.0

HEMAT

Citations per year, relative to Nicola Tyson Nicola Tyson (= 1×) peers Noriyuki Chiba

Countries citing papers authored by Nicola Tyson

Since Specialization

Citations

This map shows the geographic impact of Nicola Tyson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Tyson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Tyson more than expected).

Fields of papers citing papers by Nicola Tyson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Tyson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Tyson. The network helps show where Nicola Tyson may publish in the future.

Co-authorship network of co-authors of Nicola Tyson

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Tyson. A scholar is included among the top collaborators of Nicola Tyson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Tyson. Nicola Tyson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Stilgenbauer, Stephan, Osman İlhan, Christoph Renner, et al.. (2015). Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. Blood. 126(23). 493–493. 13 indexed citations

2.

Byrd, John C., Joseph M. Flynn, Thomas J. Kipps, et al.. (2015). Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 127(1). 79–86. 56 indexed citations

3.

Flynn, Joseph M., John C. Byrd, Thomas J. Kipps, et al.. (2014). Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.. Journal of Clinical Oncology. 32(15_suppl). 7083–7083. 18 indexed citations

4.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2012). Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals of the Rheumatic Diseases. 72(9). 1496–1502. 283 indexed citations

5.

Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2012). THU0120 Long-term safety of rituximab: 10-year follow-up in the rheumatoid arthritis global clinical trial programme. Annals of the Rheumatic Diseases. 71. 195–195. 5 indexed citations

6.

Mease, Philip J., Ronald van Vollenhoven, Patrick Durez, et al.. (2012). FRI0201 Analysis of infection risk in patients with limited return of peripheral B cells after a period of 2 years or more following any rituximab treatment course in RA clinical trials. Annals of the Rheumatic Diseases. 71. 381–381. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact